Yale Cancer Center is pleased to announce the appointments of Thomas Prebet, M.D., Ph.D., as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program. In these new roles, Prebet and Zeidan will work closely with Stephanie Halene, M.D., Ph.D., Interim Chief of Hematology at YCC.
Prebet is an Associate Professor of Medicine (Hematology) and is focused on developing clinical trials for myeloid malignancies and translational advances for patients with acute myeloid leukemia and myelodysplastic syndromes. In his new role as DART leader for myeloid malignancies, he will oversee the clinical trial team for myeloid malignancies and work to develop a complete portfolio of trials for our patients.
Zeidan is an Associate Professor of Medicine (Hematology) and is the Yale principal investigator for multiple NCI-sponsored and clinical trials in myeloid malignancies. Zeidan is also chairing the steering committee for a large pharma-sponsored randomized trial of myelodysplastic syndromes (MDS). As Director of the Hematology Early Therapeutics Program, Zeidan will partner closely with Patricia LoRusso, D.O., Associate Cancer Center Director for Experimental Therapeutics at YCC, to develop a comprehensive Phase I clinical trial portfolio for patients with hematologic malignancies.
Prebet and Zeidan start their new roles immediately.